anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A compound expressed by formula I [R is halogen, OH, lower alkyl, lower alkoxy or (lower alkyl-substituted) carboxyl] or salt thereof. EXAMPLE:N-(4'-Methylphenyl)-guanidinomethylbenzamide. USE:An antiulcer agent capable of being orally or parenterally (e.g. intramuscular injection, subcuteaneous administration, etc.) administered for treating humans and other warm-blooded animals. PREPARATION:For example, 1.0mol 4-guanidinomethylbenzoic acid expressed by formula II is reacted with an aniline derivative expressed by formula III in an amount of 1.0-1.5mol based on the compound expressed by formula II in the presence of dicyclohexylcarbodiimide or phosphorus trichloride to afford the aimed compound expressed by formula I. The reaction is preferably carried out by using anhydrous acetone, THF, dioxane, etc.
A drug and/or pharmaceutical composition comprising recombinant mistletoe lectins for treating metastatic tumors, including malignant melanoma such as stage IV malignant melanoma, and use of said drug, particularly in select patient populations, are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain or fragments thereof. Alternatively, the recombinant mistletoe lectin polypeptides can be mistletoe lectin B-chain or fragments thereof. The drug can be used for the treatment of stages III and IV of a metastatic tumor or skin cancer, as well as to treat non-responders and therapeutic failures of a standard tumor therapy. The drug can be used in a dosage in a range of 3-7 ng recombinant mistletoe lectin per kg body weight. The dosage of the recombinant mistletoe lectin can also be 200-500 ng, independently of body weight. The drug can be administered once a week, or more frequently.
Isolated, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin HSCs) contain endothelial progenitor cells (EPCs) capable of rescuing retinal blood vessels and neuronal networks in the eye. Preferably at least about 20% of the cells in the isolated Lin HSCs express the cell surface antigen CD31. The isolated Lin HSC populations are useful for treatment of ocular vascular diseases. In a preferred embodiment, the Lin HSCs are isolated by extracting bone marrow from an adult mammal; separating a plurality of monocytes from the bone marrow; labeling the monocytes with biotin-conjugated lineage panel antibodies to one or more lineage surface antigens; removing of monocytes that are positive for the lineage surface antigens from the plurality of monocytes, and recovering a Lin HSC population containing EPCs. Isolated Lin HSCs that have been transfected with therapeutically useful genes are also provided, and are useful for delivering genes to the eye for cell-based gene therapy. Methods of preparing isolated stem cell populations of the invention, and methods of treating ocular diseases and injury are also described.
Invention herewith described refers to the herbal extract for the preparation of dietetic product with the supportive acting in chemotherapy is a phytopharmacological product based on a water-ethanol extract of the herbal mixture. The herbal extract is derived from 17 plant species whose geographic origin is from Serbia. The extract is obtained by four-day maceration of the plant material in 600 ml of 7% water-ethanol solution. The ratio of the plant material mixture to the solution is 1:5,5. Subsequently, the extract is filtered through the filter paper in the Büchner funnel. The technical problem to be solved by this invention is the extract that aims to improve efficiency and reduce side effects of chemotherapy in patients with breast cancer.
Autism spectrum disorders (ASD) affect approximately 1.1% of late adolescents and young adults, making it one of the most common neurodevelopmental disorders. Comorbid anxiety disorders affect many higher-functioning adolescents and young adults with ASD, causing substantial distress and impairment over and above that caused by an ASD diagnosis alone. While cognitive-behavioral therapy (CBT) is a first-line treatment for anxiety disorders among typically developing late adolescents, and work by the investigative team supports its utility in children with ASD and comorbid anxiety, very few evidence-based treatment approaches exist for late adolescents with ASD and comorbid anxiety. Accordingly, the investigators are proposing to develop a CBT protocol for clinical anxiety that is personalized to the unique clinical characteristics of late adolescents (ages 16-21 years) with ASD namely, the Treatment of Anxiety in Late Adolescents with Autism (TALAA). Initial TALAA development efforts will focus on adapting relevant treatment elements from an efficacious CBT program for early adolescents with ASD and comorbid anxiety to the characteristics and clinical needs of the age group. Developmentally appropriate, novel treatment components will be added, including those focusing on fostering successful transitions to adulthood (e.g., work readiness). In response to the NIH Roadmap Initiative, attention will be paid to protocol adaptability with varying clinical presentations. Measures of treatment integrity and competence will be developed. Thereafter, protocol and measure development will be refined through our experiences treating 8 young adults (ages 16-21 years) with ASD and comorbid anxiety disorder(s) as well as through clinician, patient, and expert feedback. The feasibility of implementing TALAA will then be examined in the context of a pilot study incorporating all the features of the planned future efficacy trial comparing TALAA to treatment as usual, but with a limited sample size (N=44).
Risk Summary

Based on the mechanism of action, COSELA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12)]. There are no available human or animal data on COSELA use to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus. 

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. However, the background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies in the United States general population.
For 15 years, the prevalence of the extended-spectrum β-lactamases producing Enterobacteriaceae (ESBLE), resistant to the 3rd generation cephalosporins, has constantly increased worldwide. Since 2010 an additional threat appeared with the emergence of the bacteria resistant to carbapenems, the antibiotic of choice in case of infection due to ESBLE. To treat the infection due to these extremely resistant strains, there are still only few molecules, as the colistin. Very quickly, the colistin resistance appeared, especially a plasmid-born resistance described in December 2015 and which has already spread a lot, most probably from an animal reservoir. The control of the resistance dissemination requires reliable tools for detection of colistin resistant isolates, in particular in immunocompromised patients, as those of intensive care unit (ICU) or oncohaematology ward, that are often exposed to multidrug resistant strains. Currently, the colistin resistance is difficult to detect and that is probably why it was underestimated for a long time and has already diffuse worldwide. Some recent tests for the detection of colistin resistant isolates have been developed and tested in laboratory. They have now to be evaluated in clinical situation in order to be correctly used and interpreted. From rectal swabs of patients admitted in ICU and oncohaematology ward, investigators will use first a new culture medium (SuperPolymyxin) for screening the colistin resistant Gram negative bacteria and then a new rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth micro-dilution (BMD) method. The isolates will be collected on the screening medium, during 12 months, from 4 centers (Mont de Marsan, Limoges, Dax, Bordeaux) and sent to Bordeaux University Hospital where the rapid test and the BMD method will be centralized.
PURPOSE:To eliminate the stickiness of the title composition and to make the composition refreshing by incorporating 5-30wt.% oil component at a 1/0.5-1/2 weight ratio of liq. oil and solid oil and wherein the liq. oil contains at least 50wt.% volatile component in the composition. CONSTITUTION:In the oil-in-water type emulsion composition used for skin cosmetics, hair cosmetics, etc., 5-30wt.% oil component consisting of liq. oil and solid oil is incorporated in the composition. The weight ratio of the liq. oil to the solid oil is controlled to 1/0.5-1/2. The content of the volatile oil component such as low-grade polymerization dimethyl polysiloxane in the liq. oil is controlled to at least 50wt.%. As a result, the stickiness and oiliness of the composition is remarkably reduced, and a light and refreshing feel can be obtained when the composition is used. Since the appropriate amt. of the oil is contained, emulsion stability is improved, and the composition is appropriately used for cream, rinse, etc.
G protein-coupled receptor 37-like 1 (GPR37L1) is an orphan GPCR with largely unknown functions. Here, we report that Gpr37l1/GRP37L1 ranks among the most highly expressed GPCR transcripts in mouse and human dorsal root ganglia (DRGs) and is selectively expressed in satellite glial cells (SGCs). Peripheral neuropathy induced by streptozotoxin (STZ) and paclitaxel (PTX) led to reduced GPR37L1 expression on the plasma membrane in mouse and human DRGs. Transgenic mice with Gpr37l1 deficiency exhibited impaired resolution of neuropathic pain symptoms following PTX- and STZ-induced pain, whereas overexpression of Gpr37l1 in mouse DRGs reversed pain. GPR37L1 is coexpressed with potassium channels, including KCNJ10 (Kir4.1) in mouse SGCs and both KCNJ3 (Kir3.1) and KCNJ10 in human SGCs. GPR37L1 regulates the surface expression and function of the potassium channels. Notably, the proresolving lipid mediator maresin 1 (MaR1) serves as a ligand of GPR37L1 and enhances KCNJ10- or KCNJ3-mediated potassium influx in SGCs through GPR37L1. Chemotherapy suppressed KCNJ10 expression and function in SGCs, which MaR1 rescued through GPR37L1. Finally, genetic analysis revealed that the GPR37L1-E296K variant increased chronic pain risk by destabilizing the protein and impairing the protein's function. Thus, GPR37L1 in SGCs offers a therapeutic target for the protection of neuropathy and chronic pain.
A salt composition containing 15-70 % of NaCl, 5-85 % of K/Mg double salts, and 0-65 wt. % of KCl, with the molar ratio of potassium to magnesium being greater than or equal to 1, was found, when used instead of table salt (NaCl), to effect an unexpectedly major lowering of the systolic and the diastolic blood pressure in human beings. A more suitable salt composition still to this end is found when such a salt composition in addition contains at least 16 wt. % of potassium chloride and, preferably, also trace elements in an amount of 0 to 2 wt. %. Notably, a beneficial effect is observed in people suffering from a mild to moderate form of hypertension.
<P>PROBLEM TO BE SOLVED: To accurately transmit the request content of image reading to a requested party in an image reading request apparatus, method and program for requesting the image reading of a medical image to an image-reading doctor.  <P>SOLUTION: A request data compilation screen 61 displays an explanation image 64 along with the medical image 54, or an image reading object. The explanation image 64 illustrates what part of the medical image 54 the requester doctor wants the requested doctor to draw attention. The explanation image 64 is generated based on data of the medical image 54. The explanation image 64 is displayed on the explanation image display part 66. When specifying an optional position inside the explanation image 64 by a pointer 53, an attention mark 72 is applied to the specified position. The explanation image 64 is added to request data with the medical image 54 and transmitted to the requested party.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The invention discloses a bovine lambda 3 interferon mutant and a preparation method and application thereof. Belongs to the field of biotechnology. The bovine lambda 3 interferon mutant is obtained by mutating the 5 th amino acid of an original sequence of the bovine lambda 3 interferon amino acid sequence with the accession number of XP _010847513.1 into arginine from cysteine and mutating the 19 th amino acid from serine into proline. Further carrying out amino acid single-site mutation, double-site mutation and multi-site mutation on the mutant to obtain a plurality of bovine lambda 3 interferon mutants with improved antiviral activity. The antiviral activity of the bovine lambda 3 interferon mutant expressed in a silkworm bioreactor by using a silkworm baculovirus expression system is greatly improved. The bovine lambda 3 interferon mutant provided by the invention can be used for preparing a medicament or a reagent for preventing or treating bovine viral diseases.
Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications. The DBDpp are antibody mimetics comprising three anti-parallel alpha helices joined by linker peptides.
Pre and post-operative Ventriject V02Max values will be taken in this group of patients to assess whether pre-operative V02Max correlates with pre-operative PPOSSUM, NELA scores and post-operative outcomes. This group of participants will answer whether acute V02Max is reflective of operative outcomes and whether it correlates with current methods of risk stratification (PPOSSUM, NELA, ASA) and post-operative outcome scores (Clavien-Dindo classification). This group is important as it will help establish whether V02Max measurements in the acute setting for operative risk stratification is feasible.
Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human fingerstick whole blood at the Point of Care (POC); i.e. in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation; and at home.

The NOWDx COVID-19 Test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Testing of human fingerstick whole blood is intended to be conducted in a home-like setting of a facility authorized to perform CLIA waived tests.
PURPOSE:To obtain an RNA fraction having a specific molecular weight and base composition of nucleic acid and exhibiting the titled activity, by extracting the cells of microorganism belonging to Streptococcus genus with hydrochloric acid and fractionating the extract by gel-filtration. CONSTITUTION:Various microbial strains belonging to Streptococcus genus (e.g. Streptococcus faecium, FERM BP-269) is cultured e.g. in Rogosa liquid medium by stationary culture, and the culture liquid is centrifuged to collect microbial cells. The cells are suspended in 0.2N hydrochloric acid, heat-treated at 100 deg.C for 5-15 min and centrifuged at 10<5> G. The supernatant fraction is neutralized and subjected to repeated dialysis and freeze-drying to obtain crude extract. The crude extract is subjected to gel-filtration and a fraction exhibiting the absorbance peak (A660nm) by oricinol method is collected. The operation is repeated to obtain the objective fraction having a molecular weight of 2,000+ or -1,000 measured by gel-filtration and the ratios uracil:guanine:cytosine: adenine=13.0:16.0:16.0:10.0.
Cutaneous squamous cell carcinoma (cSCC) ranks as the second most prevalent skin tumour (excluding melanoma). However, the molecular mechanisms driving cSCC progression remain elusive. This study aimed to investigate GBP1 expression in cSCC and elucidate its potential molecular mechanisms underlying cSCC development. GBP1 expression was assessed across public databases, cell lines and tissue samples. Various assays, including clone formation, CCK8 and EdU were employed to evaluate cell proliferation, while wound healing and transwell assays determined cell migration and invasion. Subcutaneous tumour assays were conducted to assess in vivo tumour proliferation, and molecular mechanisms were explored through western blotting, immunofluorescence and immunoprecipitation. Results identified GBP1 as an oncogene in cSCC, with elevated expression in both tumour tissues and cells, strongly correlating with tumour stage and grade. In vitro and in vivo investigations revealed that increased GBP1 expression significantly enhanced cSCC cell proliferation, migration and invasion. Mechanistically, GBP1 interaction with SP1 promoted STAT3 activation, contributing to malignant behaviours. In conclusion, the study highlights the crucial role of the GBP1/SP1/STAT3 signalling axis in regulating tumour progression in cSCC. These findings provide valuable insights into the molecular mechanisms of cSCC development and offer potential therapeutic targets for interventions against cSCC.
### 

Wheal and Flare: Human histamine skin wheal studies following single and repeated 5 mg doses of desloratadine have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal tachyphylaxis within the desloratadine 5 mg group over the 28-day treatment period. The clinical relevance of histamine wheal skin testing is unknown.

### 

Effects on QTc: In clinical trials for CLARINEX-D 12 HOUR Extended Release Tablets, ECGs were recorded at baseline and endpoint within 1 to 3 hours after the last dose. The majority of ECGs were normal at both baseline and endpoint. No clinically meaningful changes were observed following treatment with CLARINEX-D 12 HOUR Extended Release Tablets for any ECG parameter, including the QTc interval. An increase in the ventricular rate of 7.1 and 6.4 bpm was observed in the CLARINEX-D 12 HOUR Extended Release Tablets and pseudoephedrine groups, respectively, compared to an increase of 3.2 bpm in subjects receiving desloratadine alone. Single daily doses of CLARINEX 45 mg were given to normal male and female volunteers for 10 days.

All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In the CLARINEX-treated subjects, there was a mean increase in the maximum heart rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate (QTc) by both Bazett's and Fridericia methods. Using the QTc (Bazett), there was a mean increase of 8.1 msec in the CLARINEX-treated subjects relative to placebo. Using QTc (Fridericia) there was a mean increase of 0.4 msec in CLARINEX-treated subjects relative to placebo. No clinically relevant adverse events were reported.
OBJECTIVES: The aim of this study was to demonstrate the feasibility of a modified sling mid-urethral suspension + subcutaneous tunnel-double point fixation technique for the treatment of male urinary incontinence and to preliminarily evaluate the short-term clinical efficacy of this technique.
PATIENTS AND METHODS: The clinical data of patients treated with the modified sling mid-urethral suspension + subcutaneous tunnel-double point fixation technique using a Pelvimesh pelvic floor repair patch as a sling were collected. The primary evaluation criteria were surgery-related indicators and daily urinal pad usage before and after treatment, and the secondary evaluation criteria were the corresponding incontinence scores and the results of surgery-related questionnaires.
RESULTS: After 1-12 months of follow-up, seven patients were clinically cured. Follow-up 1 month after surgery showed that one patient (14.3%) used one pad daily, and six patients (85.7%) did not need pads. The incontinence quality of life questionnaire (I-QOL) scores at 3 days and 1 month postoperatively were 89.4 ± 2.5 and 88.1 ± 6.7, respectively, which were significantly higher than the preoperative scores (31.5 ± 18.9) (P < 0.05). The scores of the International Continence Control Association Incontinence Questionnaire Short Form (ICI-Q-SF) at 3 days and 1 month postoperatively were 3.2 ± 0.9 and 4.2 ± 1.7, respectively, which were significantly lower than the preoperative scores of 19.4 ± 5.0 (P < 0.05). In addition, the results of the surgery-related questionnaires were positive. No serious complications occurred in any of the patients.
CONCLUSION: The modified sling mid-urethral suspension + subcutaneous tunnel-double point fixation technique for the treatment of male urinary incontinence patients is safe, effective, minimally invasive, and has few complications. However, further validation in large sample, randomized, comparative, and longer-term follow-up studies is still needed.
PURPOSE:To obtain a physiologically active substance soluble in water, free from bitter taste, and effective for the remedy of trauma, etc., with a simple method, by treating the sap of aloe batchwise with activated charcoal, and collecting the treated product. CONSTITUTION:The sap collected from aloe such as Aloe vera, Aloe arborescens, etc. is treated batchwise with activated charcoal, and the charcoal is removed to obtain a liquid containing a physiologically active substance. The liquid is free from colored component and water-insoluble component, and has excellent stability and safety. If necessary, water is distilled out from the liquid to obtain powdery substance. When a heat treatment and extraction with a water-soluble organic solvent are carried out in combination with the activated charcoal treatment, the impurities can be removed more certainly. The resultant substance is effective as an external drug, cosmetic, etc. Since the substance has delicious sour taste, it can be used also as a health drink, medical wine, toothpaste, mouthwash, etc.
Participants will be screened for Hepatitis C using the Finger-stick whole blood HCV RNA Point of Care GeneXpert. Participants with hepatitis C will be offered treatment with a pan-genotypic DAA HCV therapy- either 12 weeks of sofosbuvir/velpatasvir or 8 weeks of glecaprevir/pibrentasvir.